(Q36627019)

15 August 2017

5 references

13 March 2019

24 March 2019

12 November 2019

21 December 2020

16 July 2021

A review of minodronic acid hydrate for the treatment of osteoporosis (English)

1 reference

organic compound, having C-P covalent bound

15 August 2017

3 references

13 March 2019

24 March 2019

12 November 2019

1 reference

12 November 2019

1 reference

21 December 2020

bone density conservation agents

1 reference

16 July 2021

Shinji Tanishima

1

1 reference

PMCID

3578444

15 August 2017

Yasuo Morio

series ordinal

2

1 reference

PMCID

3578444

15 August 2017

language of work or name

English

0 references

publication date

15 February 2013

6 references

Clinical Interventions in Aging

15 August 2017

13 March 2019

24 March 2019

12 November 2019

21 December 2020

16 July 2021

6 references

15 August 2017

13 March 2019

24 March 2019

12 November 2019

21 December 2020

16 July 2021

8

1 reference

15 August 2017

185-189

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

15 August 2017

start time

1 February 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Cellular mechanisms of bone remodeling

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Adverse effects of bisphosphonates: current issues.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Safety considerations with bisphosphonates for the treatment of osteoporosis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Pathogenesis of osteoporosis: concepts, conflicts, and prospects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Epidemiology and outcomes of osteoporotic fractures

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Minodronate for the treatment of osteoporosis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Minodronic acid influences receptor activator of nuclear factor kappaB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Risk of Mortality Following Clinical Fractures

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3578444

Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23440003

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2147/CIA.S23927

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

PMCID

3578444